Skip to main content

Table 3 Optimized Predictive Analysis for pathological complete response and treatment cost per patient

From: The addition of neoadjuvant pertuzumab for the treatment of HER2+ breast cancer: a cost estimate with real-world data

Predictors of pathological complete response (Multivariable logistic regression)

 

Pathological complete response ypT0/is ypN0

Pathological complete response in the breast

 

Adjusted OR (95% CI)

P-value

Adjusted OR (95% CI)

P-value

Regimen

 AC-DH

1

 

1

 

 AC-DHP

1.65 (0.63–4.30)

0.304

1.51 (0.58–3.94)

0.396

Clinical staging

 II

1

 

1

 

 III

0.14 (0.04–0.43)

0.001

0.14 (0.04–0.44)

0.001

Hormonal Receptors (ER and PR)

 Both negative

1

 

1

 

 At least one positive

0.21 (0.08–0.59)

0.003

0.16 (0.06–0.43)

< 0.001

Predictors of treatment cost per patient (Gamma General Model)

 

Cost per patient

Regimen

Adjusted MCR (95% CI)

P-value

AC-DH

1

 

AC-DHP

1.40 (1.30–1.49)

< 0.001

  1. AC-DH, doxorubicin, cyclophosphamide, docetaxel plus trastuzumab. AC-DHP, doxorubicin, cyclophosphamide, docetaxel, trastuzumab plus pertuzumab. ER, estrogen receptor. PR, progesterone receptor